SCHEMBL2675992

SCHEMBL2675992

O=C(O)c1c(CN2CCNC(c3cccc(Cl)c3)C2)n(-c2ccccc2)c(=O)c2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.37
GSK3B P49841 2/20 0.36
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR7 P34969 1/20 0.35
HTR1A P08908 2/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
DOCK5 Q9H7D0 1/20 0.34
MEN1 O00255 2/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 2/20 0.34
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1717159 0.85 TACR3 (0.41) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2675283 0.85 REN (0.35) MAPTNPSR1HTR7GAAMEN1
SCHEMBL2676367 0.85 MEN1 (0.37) SMN1; SMN2MAPTNPSR1HTR7GAA
SCHEMBL2676871 0.81 REN (0.46) NPSR1KDM4EMAPK1ADRB1REN
SCHEMBL2677142 0.81 REN (0.46) NPSR1KDM4EMAPK1ADRB1REN
SCHEMBL2676873 0.81 REN (0.46) NPSR1KDM4EMAPK1ADRB1REN
SCHEMBL2676671 0.78 REN (0.40) MAPTNPSR1KDM4EMAPK1ADRB1
SCHEMBL2675559 0.77 REN (0.45) NPSR1SIGMAR1MAPK1RENTSHR
SCHEMBL2676125 0.76 REN (0.43) CYP3A4CYP2D6REN
SCHEMBL2676121 0.76 REN (0.43) CYP3A4CYP2D6REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 SMN1; SMN2 4742/4885GSK3B 2388/4885MAPT 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.